Press Enter to search · ESC to close

Crypto

AR1001 Alzheimer’s Phase III Topline Data to Debut at CTAD 2026

The global pivotal Phase III POLARIS-AD trial of oral Alzheimer’s drug AR1001 will report topline results as an oral presentation at the 19th Clinical Trials on Alzheimer’s Disease congress (CTAD 2026), held November 16-19 in Boston, with the data first disclosed on November 16. Fosun Pharma holds regional licensing rights and exclusive options in core global markets for the oral disease-modifying candidate.

Share

Related News

新云社 share card
Long-press image above → Save to Photos / Share
Pitch us Feedback